Despite major improvements in outcome over the past decades, acute myeloid leukemia (AML)
remains a life-threatening malignancy in children, with current survival rates of ∼ 70%. …

Diagnosis, treatment, response monitoring, and outcome of pediatric acute myeloid leukemia
(AML) have made enormous progress during the past decades. Because AML is a rare …

Pediatric acute myeloid leukemia (AML) represents 15%–20% of all pediatric acute
leukemias. Survival rates have increased over the past few decades to ~70%, due to improved …

Chromosomal rearrangements of the human MLL/KMT2A gene are associated with infant,
pediatric, adult and therapy-induced acute leukemias. Here we present the data obtained …

We present the molecular landscape of pediatric acute myeloid leukemia (AML) and
characterize nearly 1,000 participants in Children's Oncology Group (COG) AML trials. The COG–…

Chromosomal rearrangements of the human MLL (mixed lineage leukemia) gene are
associated with high-risk infant, pediatric, adult and therapy-induced acute leukemias. We used …

Purpose Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19 on
B-cell lymphoblasts. We evaluated the safety, pharmacokinetics, recommended dosage, and …

Although imatinib, a BCR-ABL tyrosine kinase inhibitor, is used to treat acute Philadelphia
chromosome–positive (Ph + ) leukemia, it does not prevent central nervous system (CNS) …

Translocations involving chromosome 11q23 frequently occur in pediatric acute myeloid
leukemia (AML) and are associated with poor prognosis. In most cases, the MLL gene is …

Leukemias that harbor translocations involving the mixed lineage leukemia gene (MLL)
possess unique biologic characteristics and often have an unfavorable prognosis. Gene …